The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,958.00
Bid: 1,951.00
Ask: 1,953.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.103%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,958.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Friday broker round-up UPDATE

Fri, 08th Nov 2013 09:21

Abcam: Canaccord Genuity moves target price from 396p to 386p and keeps a sell recommendation. N+1 Singer shifts target price from 450p to 445p downgrading to sell.Aberdeen Asset Management: Jefferies lowers target price from 440p to 430p and reiterates a hold recommendation.Anglo American: Goldman Sachs ups target price from 1100p to 1130p, but still recommends selling.Associated British Foods: Canaccord Genuity moves target price from 1663p to 1680p, but still recommends selling.BAE Systems: Investec cuts target price from 485p to 460p and downgrades from buy to hold.Betfair Group: HSBC initiates with a target price of 1245p and an overweight rating.Bovis Homes Group: Jefferies raises target price from 995p to 1022p and keeps a buy recommendation. Panmure Gordon shifts target price from 873p to 875p and maintains a buy recommendation.Cable & Wireless Communications: Alphavalue shifts target price from 55p to 54.8p and downgrades from buy to add. Espirito Santo shifts target price from 60p to 62p and keeps a buy recommendation.Clarkson: JP Morgan increases target price from 1670p to 1990p and maintains a neutral rating.Dairy Crest Group: JP Morgan raises target price from 543p to 583p keeping an overweight rating.easyJet: Investec cuts target price from 1550p to 1500p, while leaving its buy recommendation unaltered.GlaxoSmithKline: Jefferies takes target price from 1600p to 1700p and retains a hold recommendation.Glencore Xstrata: Investec initiates with a target price of 307p and a sell recommendation.Halfords Group: N+1 Singer raises target price from 475p to 540p and leaves its buy recommendation unchanged. Citi increases target price from 465p to 545p and maintains a buy recommendation. JP Morgan ups target price from 405p to 440p reiterating an overweight rating.Hikma Pharmaceuticals: Panmure Gordon ups target price from 1300p to 1350p retaining a buy recommendation.Inmarsat: JP Morgan cuts target price from 800p to 780p and reiterates an overweight rating. HSBC reduces target price from 750p to 720p leaving its neutral rating unaltered. Societe Generale cuts target price from 670p to 650p and keeps a sell recommendation.Ladbrokers: HSBC starts with a target price of 260p and a neutral rating.Lancashire Holdings: Deutsche Bank lowers target price from 816p to 807p downgrading to hold.London Mining: JP Morgan reduces target price from 215p to 200p keeping its overweight rating.Lonmin: Investec cuts target price from 280p to 266p and downgrades from reduce to sell.Novae Group: Canaccord Genuity raises target price from 520p to 575p and maintains a buy recommendation.Pennon Group: HSBC moves target price from 760p to 740p, while upgrading to overweight.Randgold Resources: Deutsche Bank raises target price from 5050p to 5200p and stays with its buy recommendation. Investec takes target price from 5018p to 5095p retaining a hold recommendation.Record: JP Morgan lowers target price from 45p to 40p, while staying with its overweight rating.Reed Elsevier: Credit Suisse raises target price from 620p to 815p, while staying with its neutral rating.Rightmove: Deutsche Bank increases target price from 2450p to 2650p maintaining a hold recommendation.Schroders: JP Morgan raises target price from 2624p to 2791p leaving its overweight rating. Credit Suisse takes target price from 2350p to 2550p and keeps a neutral rating.Shanks Group: Jefferies moves target price from 110p to 121p and reiterates a hold recommendation. Credit Suisse downgrades from outperform to neutral with a target price of 110p.Tate & Lyle: Societe Generale revises target price from 865p to 900p and stays with its buy recommendation.Waterlogic: Liberum Capital lowers target price from 120p to 110p retaining its hold recommendation. N+1 Singer reduces target price from 235p to 136p, while leaving its buy recommendation unchanged.Weir Group: Berenberg shifts target price from 2680p to 2675p keeping a buy recommendation. Espirito Santo initiates with a target price of 2600p and a buy recommendation.William Hill: HSBC initiates with a target price of 385p and an underweight rating.Wincanton: JP Morgan ups target price from 91p to 106p, while staying with its underweight rating.
More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.